Summary: In an article covering unique and innovative approaches to funding psychedelic research, Bloomberg highlights the perspective shared by MAPS Public Benefit Corporation (MAPS PBC) CEO Amy Emerson at the recent conference Horizons: Perspectives on Psychedelics in New York City.
“This space could become dominated by companies whose primary obligation is to shareholders,” Emerson said at the conference. “Let’s not do that. That’s why we’re all here.”
